PREV VIDEO NEXT VIDEO MORE VIDEOS

MaxCyte (MXCT) presentation at ShareSoc July 2018

Driving the next generation of cell-based medicines
By Doug Doerfler – Founder, President & CEO

Introduction – 00:23
Background and what MaxCyte does – 02:41
Business model – 04:11
CARMA platform, CAR therapy in oncology – 09:07
Cell therapy programmes – business model – 16:12
Revenue potential across multiple applications – 19:15
Expected news flow – 21:36
Summary & outlook – 22:18
2017 financial highlights – 22:50
Q&A – 23:45

 

Presentation slides can be viewed here.

You might be interested in

Private Investor World content is for general information and interest. It does not constitute any kind of recommendation or inducement to buy shares of any company. Private Investor World is not offering any kind of financial advice, and nothing in our content should be taken as such. For these reasons any Private Investor World content falls outside the scope of FCA regulation.
CLOSE